Expression of pS2 estrogen-inducible protein in primary breast cancer.
The expression of pS2 estrogen-inducible protein was investigated using formalin-fixed, paraffin-embedded sections from 210 primary breast cancers. One hundred and three (49%) out of 210 cases were positive for pS2. A significant correlation existed between pS2 expression and hormone receptor status. Patients with pS2 expression had better overall survival and a longer survival time after the first recurrence than those without pS2 expression. By multivariate analysis, pS2 was not an independent prognostic indicator, but pS2 expression was a possible indicator for responsiveness to treatment in relapsed breast cancer patients.
Horiguchi
J
J
Second Department of Surgery, Gunma University School of Medicine, Maebashi, Japan.
Iino
Y
Y
Takei
H
H
D000328:Adult; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D011506:Proteins; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D016019:Survival Analysis; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins
D009363:Neoplasm Proteins; D011506:Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C051838:TFF1 protein, human; D000071163:Trefoil Factor-1; D025521:Tumor Suppressor Proteins